Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 32

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 32
---
 of patent protection for our drug candidates. If the latest-expiring patent is invalidated
or held unenforceable, in whole or in part, the overall protection for the drug candidate may be adversely affected.

Our inability to protect our trademarks, patents and trade secrets may prevent us from successfully marketing our products and competing effectively.

Failure to protect
our intellectual property could harm our brand and our reputation and adversely affect our ability to compete effectively. Further, enforcing
or defending our intellectual property rights, including our licensing rights trademarks, patents, copyrights and know-how, could result
in the expenditure of significant financial and managerial resources. We regard our intellectual property, particularly our trademarks,
patents and trade secrets to be of considerable value and importance to our business and our success. We rely on a combination of trademark,
patent, and trade secrecy laws, confidentiality procedures and contractual provisions to protect our intellectual property rights. There
can be no assurance that the steps taken by us to protect these proprietary rights will be adequate or that third parties will not infringe
or misappropriate our trademarks, patented processes, trade secrets or similar proprietary rights. In addition, there can be no assurance
that other parties will not assert infringement claims against us, and we may have to pursue litigation against other parties to assert
our rights. Any such claim or litigation could be costly. In addition, any event that would jeopardize our proprietary rights or any
claims of infringement by third parties could have a material adverse effect on our ability to market or sell our brands, profitably
exploit our products or recoup our associated research and development costs.

<div align='center'>16</div>

The patenting process, enforcement of issued patents, and defense against claims of infringement are inherently risky.

The strength of our
patent portfolio is an important factor that will influence our success. Securing patent approval for the ARB-based anti-cancer adjunct
drug candidate and for the LPLT based vaccination technology is essential to safeguard our investment and maintain a competitive position
in the market. Patents give the patent holder the right to prevent others from using its patented technology. If someone infringes upon
the patented material of a patent holder, the patent holder has the right to initiate legal proceedings against that person to protect
its patented material. These proceedings, however, can be lengthy and costly. We perform an ongoing review of our patent portfolio to
confirm that our key technologies are adequately protected. If we determine that any of our patents require either additional disclosures
or revisions to